Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine A Janeway

Showing results (51-60 of 144) with videos related to

Pageof 15
Sort By:
Pediatric Blood & Cancer|November 1, 2018
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology GroupMichael S Isakoff, Robert Goldsby, Doojduen Villaluna, et al.
Plos One|May 30, 2013
Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]Lorna Kelly, Kenneth Bryan, Su Young Kim, et al.
Pediatric Blood & Cancer|August 19, 2023
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumorsAndrew Groves, Abigail Ward, Yvonne Y Li, et al.
Pediatric Blood & Cancer|December 19, 2017
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcomaLillian M Guenther, R Grant Rowe, Patricia T Acharya, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology GroupLisa M Kopp, Suman Malempati, Mark Krailo, et al.
Pediatric Blood & Cancer|April 30, 2016
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor CommitteeMichael W Bishop, Yu-Chen Chang, Mark D Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in ChildhoodSurya P Rednam, Ayelet Erez, Harriet Druker, et al.
British Journal of Cancer|October 11, 2022
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology GroupDavid S Shulman, Sonja Chen, David Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Pageof 15

Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
Pediatric Blood & Cancer|November 1, 2018
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology GroupMichael S Isakoff, Robert Goldsby, Doojduen Villaluna, et al.
Plos One|May 30, 2013
Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]Lorna Kelly, Kenneth Bryan, Su Young Kim, et al.
Pediatric Blood & Cancer|August 19, 2023
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumorsAndrew Groves, Abigail Ward, Yvonne Y Li, et al.
Pediatric Blood & Cancer|December 19, 2017
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcomaLillian M Guenther, R Grant Rowe, Patricia T Acharya, et al.
JCO Precision Oncology|January 4, 2019
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPam K Mangat, Susan Halabi, Suanna S Bruinooge, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology GroupLisa M Kopp, Suman Malempati, Mark Krailo, et al.
Pediatric Blood & Cancer|April 30, 2016
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor CommitteeMichael W Bishop, Yu-Chen Chang, Mark D Krailo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in ChildhoodSurya P Rednam, Ayelet Erez, Harriet Druker, et al.
British Journal of Cancer|October 11, 2022
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology GroupDavid S Shulman, Sonja Chen, David Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Pageof 15